In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theraclone Sciences Inc.

www.theraclone-sciences.com

Latest From Theraclone Sciences Inc.

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

Deals Business Strategies

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

Deals M & A

Venture Funding Deals, November 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.

BioPharmaceutical Medical Device

FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump

Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.

Metabolic Disorders Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Theraclone Sciences Inc.
  • Senior Management
  • Clifford J Stocks, CEO
    Russ Hawkinson, CFO
    Kristine Swiderek, PhD, CSO
  • Contact Info
  • Theraclone Sciences Inc.
    Phone: (206) 805-1600
    1124 Columbia St., Ste. 300
    Seattle, WA 98104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register